Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C

Inclusion Criteria: 1. Histologically proven colon cancer stage Dukes' C. 2. Patient over 18 years. 3. WHO performance status \<1. 4. Adequate haematological function (Hb ≥ 100 g/L, ANC ≥ 2.0 x 109/L, platelets ≥ 150 x 109/L) 5. Adequate renal and hepatic functions: serum creatinine and total bilirubin ≤ 1.25 times upper normal limits (ASAT and ALAT ≤ 3 times upper normal limits) 6. Clinical evaluation, haematology and biochemistry performed within 1 week prior to the start of chemotherapy 7. Use of adequate contraception (males with reproductive potential) 8. Written informed consent given Exclusion Criteria: 1. Other tumour types than colon adenocarcinomas 2. Current severe neutropenia, leucopenia or thrombocytopenia 3. Severely reduced liver or renal function 4. Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or ulcerative colitis 5. Current chronic diarrhoea 6. Contraindication for corticosteroid administration 7. History of prior serious allergic or pseudo-allergic reaction 8. Any other serious illness or medical condition 9. Symptomatic peripheral neuropathy ≥ grade 2 10. Received mangafodipir ≤ 5 weeks before planned start of chemotherapy 11. Received any of the FOLFOX drugs ≤ 5 weeks before planned start of chemotherapy 12. Any plans of administered other anti-cancer therapy (including radiotherapy) concurrent with this study 13. Fertile females 14. Males with reproductive potential not implementing adequate contraception measures 15. Phaeochromocytoma